- Pediatric Critical Care Medicine
- Neurocritical Care
Associate Medical Director, Pediatric Intensive Care Unit (2020 - Present)
Director Pediatric Neurocritical care, Critical Care Medicine (2018 - Present)
Boards, Advisory Committees, Professional Organizations
Co-Chair, Brain & Behavior Quality Assurance and Performance Improvement Committee (2019 - Present)
Co-Chair, Professional Practice Evaluation Committee. Lucile Packard Children’s Hospital, Stanford University (2018 - Present)
Appointed Committee Member, Post Graduate and Fellowship Education Committee, Society of Critical Care Medicine (SCCM) (2017 - Present)
Member, Society of Critical Care Medicine (SCCM) (2013 - Present)
Member, Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) (2016 - Present)
Member, Pediatric Neurocritical Care Research Group (PNCRG) (2016 - Present)
Member, Neurocritical Care Society (NCS) Pediatric Neurocritical Care Section (2018 - Present)
Member, Council on Child Abuse and Neglect (COCAN), American Academy of Pediatrics (2019 - Present)
Fellow, American Academy of Pediatrics (2017 - Present)
Medical Education: Medical College Of Wisconsin Office of Graduate Medical Education (2010) WI
Board Certification: American Board of Pediatrics, Pediatric Critical Care Medicine (2016)
Fellowship: Johns Hopkins University School of Medicine (2016) MD
Board Certification: American Board of Pediatrics, Pediatrics (2013)
Residency: Children's National Medical Center (2013) DC
Current Research and Scholarly Interests
My research interests reside in the field of Neurocritical Care Medicine. My research focus has included inflammation following traumatic brain injury, outcome prediction after cardiac arrest, and neuro-monitoring in the pediatric intensive care setting. These interests are integrated clinically to focus on the merging of specialized neurologic monitoring and care with prognostic efforts in critically ill patients.
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG)
The primary purpose of this study is to test whether GD2-CAR T cells can be successfully made from immune cells collected from children and young adults with H3K27M-mutant diffuse intrinsic pontine glioma (DIPG) or spinal H3K27M-mutant diffuse midline glioma (DMG). H3K27Mmutant testing will occur as part of standard of care prior to enrollment.
Continuing Care For Critically Ill Children Beyond Hospital Discharge: Current State of Follow-up.
OBJECTIVES: Survivors of the PICU face long-term morbidities across health domains. In this study, we detail active PICU follow-up programs (PFUPs) and identify perceptions and barriers about development and maintenance of PFUPs.METHODS: A web link to an adaptive survey was distributed through organizational listservs. Descriptive statistics characterized the sample and details of existing PFUPs. Likert responses regarding benefits and barriers were summarized.RESULTS: One hundred eleven respondents represented 60 institutions located in the United States (n = 55), Canada (n = 3), Australia (n = 1), and the United Kingdom (n = 1). Details for 17 active programs were provided. Five programs included broad PICU populations, while the majority were neurocritical care (53%) focused. Despite strong agreement on the need to assess and treat morbidity across multiple health domains, 29% were physician only programs, and considerable variation existed in services provided by programs across settings. More than 80% of all respondents agreed PFUPs provide direct benefits and are essential to advancing knowledge on long-term PICU outcomes. Respondents identified "lack of support" as the most important barrier, particularly funding for providers and staff, and lack of clinical space, though successful programs overcome this challenge using a variety of funding resources.CONCLUSIONS: Few systematic multidisciplinary PFUPs exist despite strong agreement about importance of this care and direct benefit to patients and families. We recommend stakeholders use our description of successful programs as a framework to develop multidisciplinary models to elevate continuity across inpatient and outpatient settings, improve patient care, and foster collaboration to advance knowledge.
View details for DOI 10.1542/hpeds.2021-006464
View details for PubMedID 35314865
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.
Diffuse intrinsic pontine glioma (DIPG) and other H3K27M-mutated diffuse midline gliomas (DMG) are universally lethal paediatric central nervous system tumours1. We previously discovered that the disialoganglioside GD2 is highly expressed on H3K27M-mutant glioma cells and demonstrated promising preclinical efficacy of GD2-directed chimeric antigen receptor (CAR) T cells2, providing the rationale for a first-in-human Phase 1 clinical trial (NCT04196413). Because CAR T-cell-induced brainstem inflammation can result in obstructive hydrocephalus, increased intracranial pressure, and dangerous tissue shifts, neurocritical care precautions were incorporated. Here we present the clinical experience from the first four patients with H3K27M-mutant DIPG/DMG treated with GD2-CAR T cells (GD2-CART) at dose level 1 (1e6 GD2-CAR T cells/kg administered intravenously). Patients who exhibited clinical benefit were eligible for subsequent GD2-CAR T infusions administered intracerebroventricularly3. Toxicity was largely related to tumor location and reversible with intensive supportive care. On-target, off-tumor toxicity was not observed. Three of four patients exhibited clinical and radiographic improvement. Proinflammatory cytokines were increased in plasma and cerebrospinal fluid (CSF). Transcriptomic analyses of 65,598 single cells from CAR T cell products and CSF elucidate heterogeneity in response between subjects and administration routes. These early results underscore the promise of this approach for H3K27M+ DIPG/DMG therapy.
View details for DOI 10.1038/s41586-022-04489-4
View details for PubMedID 35130560
Prevalence and Risk Factors of Neurologic Manifestations in Hospitalized Children Diagnosed with Acute SARS-CoV-2 or MIS-C.
1800; 128: 33-44
BACKGROUND: Our objective was to characterize the frequency, early impact, and risk factors for neurological manifestations in hospitalized children with acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or multisystem inflammatory syndrome in children (MIS-C).METHODS: Multicenter, cross-sectional study of neurological manifestations in children aged <18years hospitalized with positive SARS-CoV-2 test or clinical diagnosis of a SARS-CoV-2-related condition between January 2020 and April 2021. Multivariable logistic regression to identify risk factors for neurological manifestations was performed.RESULTS: Of 1493 children, 1278 (86%) were diagnosed with acute SARS-CoV-2 and 215 (14%) with MIS-C. Overall, 44% of the cohort (40% acute SARS-CoV-2 and 66% MIS-C) had at least one neurological manifestation. The most common neurological findings in children with acute SARS-CoV-2 and MIS-C diagnosis were headache (16% and 47%) and acute encephalopathy (15% and 22%), both P<0.05. Children with neurological manifestations were more likely to require intensive care unit (ICU) care (51% vs 22%), P<0.001. In multivariable logistic regression, children with neurological manifestations were older (odds ratio [OR] 1.1 and 95% confidence interval [CI] 1.07 to 1.13) and more likely to have MIS-C versus acute SARS-CoV-2 (OR 2.16, 95% CI 1.45 to 3.24), pre-existing neurological and metabolic conditions (OR 3.48, 95% CI 2.37 to 5.15; and OR 1.65, 95% CI 1.04 to 2.66, respectively), and pharyngeal (OR 1.74, 95% CI 1.16 to 2.64) or abdominal pain (OR 1.43, 95% CI 1.03 to 2.00); all P<0.05.CONCLUSIONS: In this multicenter study, 44% of children hospitalized with SARS-CoV-2-related conditions experienced neurological manifestations, which were associated with ICU admission and pre-existing neurological condition. Posthospital assessment for, and support of, functional impairment and neuroprotective strategies are vitally needed.
View details for DOI 10.1016/j.pediatrneurol.2021.12.010
View details for PubMedID 35066369
GD2 CAR T cells mediate clinical activity and manageable toxicity in children and young adults with DIPG and H3K27M-mutated diffuse midline gliomas.
AMER ASSOC CANCER RESEARCH. 2021
View details for Web of Science ID 000680263501014
- SINGLE CELL RNA SEQUENCING FROM THE CSF OF SUBJECTS WITH H3K27M+DIPG/DMG TREATED WITH GD2 CAR T-CELLULAR THERAPY OXFORD UNIV PRESS INC. 2021: 39
- Sedation and Analgesia in Brain-Injured Children Sedation and Analgesia for the Pediatric Intensivist: A Clinical Guide Springer. 2020; 1
NAUSEA AND VOMITING AFTER CRANIOTOMY IN THE PEDIATRIC ICU: INCIDENCE AND VARIATIONS IN PRACTICE
LIPPINCOTT WILLIAMS & WILKINS. 2020
View details for Web of Science ID 000530000201648
Characteristics of Pediatric Extracorporeal Membrane Oxygenation Programs in the United States and Canada.
ASAIO journal (American Society for Artificial Internal Organs : 1992)
The aim of this study was to evaluate the current infrastructure and practice characteristics of pediatric extracorporeal membrane oxygenation (ECMO) programs. A 40-question survey of center-specific demographics, practice structure, program experience, and support network utilized to cannulate and maintain a pediatric patient on ECMO was designed via a web-based survey tool. The survey was distributed to pediatric ECMO programs in the United States and Canada. Of the 101 centers that were identified to participate, 41 completed the survey. The majority of responding centers are university affiliated (73%) and have an intensive care unit (ICU) with 15-25 beds (58%). Extracorporeal membrane oxygenation has been offered for >10 years in 85% of the centers. The median number of total cannulations per center in 2017 was 15 (interquartile range [IQR] = 5-30), with the majority occurring in the cardiovascular intensive care unit (median = 13, IQR = 5-25). Fifty-seven percent of responding centers offer ECPR, with a median number of four cases per year (IQR = 2-7). Most centers cannulate in an operating room or ICU; 11 centers can cannulate in the pediatric ED. Sixty-three percent of centers have standardized protocols for postcannulation management. The majority of protocols guide anticoagulation, sedation, or ventilator management; left ventricle decompression and reperfusion catheter placement are the least standardized procedures. The majority of pediatric ECMO centers have adopted the infrastructure recommendations from the Extracorporeal Life Support Organization. However, there remains broad variability of practice characteristics and organizational infrastructure for pediatric ECMO centers across the United States and Canada.
View details for DOI 10.1097/MAT.0000000000001311
View details for PubMedID 33181543
Trauma Bay Disposition of Infants and Young Children With Mild Traumatic Brain Injury and Positive Head Imaging
Pediatric Critical Care Medicine
View details for DOI 10.1097/PCC.0000000000002033
INFRASTRUCTURE AND PRACTICE CHARACTERISTICS OF PEDIATRIC ECMO PROGRAMS ACROSS NORTH AMERICA
LIPPINCOTT WILLIAMS & WILKINS. 2019
View details for Web of Science ID 000498593402110
A Case Series of Parechovirus Encephalopathy: Apnea and Autonomic Dysregulation in Critically Ill Infants
JOURNAL OF CHILD NEUROLOGY
2018; 33 (12): 788–93
This article aims to describe a rare cause of severe encephalitis in 2 cases of infants with signs of intracranial hypertension and severe autonomic dysregulation. The authors conclude that human parechoviruses are becoming a more recognized cause of encephalitis because of the increasing use of rapid detection methods. With early recognition of this clinical entity, improved care can be administered.
View details for DOI 10.1177/0883073818789317
View details for Web of Science ID 000444976000007
View details for PubMedID 30105932
- Traumatic Injury Leads to Inflammation and Altered Tryptophan Metabolism in the Juvenile Rabbit Brain JOURNAL OF NEUROTRAUMA 2019; 36 (1): 74–86
- Neurocritical Care for Severe Pediatric Traumatic Brain Injury Medscap Drugs and Diseases. 2018
Albuterol Use in Children Hospitalized with Human Metapneumovirus Respiratory Infection
INTERNATIONAL JOURNAL OF PEDIATRICS
Introduction. Human metapneumovirus (HMPV) is a paramyxovirus from the same subfamily as respiratory syncytial virus (RSV) and causes similar acute lower respiratory tract infection. Albuterol in the setting of acute RSV infection is controversial and has not yet been studied in HMPV. We sought to determine the frequency of albuterol use in HMPV infection and the association between albuterol administration and patient outcomes. Methods. We conducted a retrospective cohort study identifying all patients hospitalized in a tertiary care children's hospital with laboratory-confirmed HMPV infection between January 2010 and December 2010. Results. There were 207 patients included in the study; 57% had a chronic medical condition. The median hospital length of stay was 3 days. Only 31% of patients in the study had a documented wheezing history, while 69% of patients received at least one albuterol treatment. There was no difference in length of stay between patients who received albuterol and those who did not. Conclusion. There is a high frequency of albuterol use in children hospitalized with HMPV infection. As with RSV, evidence may not support routine use of bronchodilators in patients with acute HMPV respiratory infection. Research involving additional patient outcomes and illness severity indicators would be useful in future studies.
View details for PubMedID 26925109
View details for PubMedCentralID PMC4748140
PERIPHERAL IMMUNE RESPONSE AFTER PEDIATRIC TRAUMATIC BRAIN INJURY IN RABBIT
MARY ANN LIEBERT, INC. 2015: A88
View details for Web of Science ID 000363949000238
Infrastructure and Practice Characteristics of Pediatric ECMO Programs in the US and Canada
Society of Critical Care Medicine
View details for DOI 10.1097/01.ccm.0000552286.86734.4f